Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

DC Migration Study to Evaluate TReg Depletion In GBM Patients With and Without Varlilumab

Trial Profile

DC Migration Study to Evaluate TReg Depletion In GBM Patients With and Without Varlilumab

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Feb 2019

At a glance

  • Drugs Temozolomide (Primary) ; Varlilumab (Primary) ; Dendritic cells; Diphtheria-tetanus vaccine
  • Indications Glioblastoma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms DERIVe
  • Most Recent Events

    • 23 Jan 2019 Planned initiation date changed from 1 Jan 2019 to 1 Mar 2019.
    • 04 Oct 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top